Paula Proszek

Royal Marsden Hospital — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index3.9kcitations300works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(136), Advanced Breast Cancer Therapies(87), Cancer Treatment and Pharmacology(41), Genetic factors in colorectal cancer(35), Lung Cancer Treatments and Mutations(29)

Publications300 total

Abstract PD2-08: Detecting subtype switching in metastatic breast cancer with circulating tumor DNA methylation profiling
Clinical Cancer Research·2026
Development of a circulating tumour DNA Assay in Patients with Malignant Pleural Mesothelioma
SSRN Electronic Journal·2026Open Access
Supplementary Figures 1-15 from Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
2025Open Access
Supplementary Tables S1 and S2 from Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA
2025Open Access
Figure 4 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Figure 2 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Figure 3 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Figure 7 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Figure 6 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Figure 1 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Figure 5 from DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
2025Open Access
Supplementary Table S8 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S13 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S7 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S12 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
Supplementary Table S10 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2025Open Access
page 1 of 15Next →

Frequent Co-authors

Michael Hubank(25), Brian A. Walker(16), Martin Kaiser(12), Faith E. Davies(12), Charlotte Pawlyn(11), Mark T. Drayson(11), Graham Jackson(11), Gareth J. Morgan(11), Eileen M. Boyle(10), Christopher P. Wardell(10), Dil Begum(10), Lynley V. Marshall(10), Nicholas C. Turner(10), John R Jones(9), David A. Cairns(9), Elisa Izquierdo(9), David González de Castro(9), David C. Johnson(8), Lorenzo Melchor(8), Walter M. Gregory(8)